| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
|
Lancet Oncol
|
2013
|
1.59
|
|
2
|
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
|
J Clin Oncol
|
2010
|
1.33
|
|
3
|
Discovery of a potent and selective aurora kinase inhibitor.
|
Bioorg Med Chem Lett
|
2008
|
1.15
|
|
4
|
Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.
|
Drug Metab Dispos
|
2008
|
1.12
|
|
5
|
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
|
Cancer Chemother Pharmacol
|
2009
|
1.08
|
|
6
|
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
|
J Thorac Oncol
|
2011
|
1.04
|
|
7
|
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
|
Clin Cancer Res
|
2012
|
1.01
|
|
8
|
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
|
Cancer Chemother Pharmacol
|
2009
|
0.93
|
|
9
|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
|
Clin Cancer Res
|
2010
|
0.91
|
|
10
|
Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family.
|
J Biol Chem
|
2002
|
0.85
|
|
11
|
2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
|
Bioorg Med Chem Lett
|
2009
|
0.84
|
|
12
|
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.
|
Bioorg Med Chem Lett
|
2008
|
0.83
|
|
13
|
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.
|
Bioorg Med Chem Lett
|
2010
|
0.82
|
|
14
|
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
|
Bioorg Med Chem Lett
|
2010
|
0.81
|
|
15
|
Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
|
Antimicrob Agents Chemother
|
2004
|
0.79
|
|
16
|
Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.
|
Bioorg Med Chem Lett
|
2008
|
0.77
|
|
17
|
Horseradish Peroxidase-Catalyzed Enantioselective Reduction of Racemic Hydroperoxy Homoallylic Alcohols: A Novel Enzymatic Method for the Preparation of Optically Active, Unsaturated Diols and Hydroperoxy Alcohols.
|
J Org Chem
|
1998
|
0.77
|